{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:40:36Z","timestamp":1790221236203,"version":"4.1.0"},"reference-count":0,"publisher":"Springer Science and Business Media LLC","issue":"Supplement 4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[1997]]},"DOI":"10.2165\/00003495-199700544-00007","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T00:28:03Z","timestamp":1236212883000},"page":"30-35","source":"Crossref","is-referenced-by-count":145,"title":["Unbedenklichkeitsaspekte bei der Anwendung von pegyliertem liposomalem Doxorubicin bei Krebspatienten"],"prefix":"10.1007","volume":"54","author":[{"given":"David S.","family":"Alberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dava J.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","container-title":["Drugs"],"original-title":[],"language":"en","deposited":{"date-parts":[[2013,1,20]],"date-time":"2013-01-20T14:34:41Z","timestamp":1358692481000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/00003495-199700544-00007"}},"subtitle":[""],"short-title":[],"issued":{"date-parts":[[1997]]},"references-count":0,"journal-issue":{"issue":"Supplement 4"},"URL":"https:\/\/doi.org\/10.2165\/00003495-199700544-00007","relation":{},"ISSN":["0012-6667"],"issn-type":[{"value":"0012-6667","type":"print"}],"subject":[],"published":{"date-parts":[[1997]]}}}